📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide. (2017)

First Author: Harrison CN

Attributed to: Unravelling biological heterogeneity in neoplastic myeloproliferative stem cells funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1182/blood-2017-05-785790

PubMed Identifier: 29074595

Publication URI: http://europepmc.org/abstract/MED/29074595

Type: Journal Article/Review

Volume: 130

Parent Publication: Blood

Issue: 17

ISSN: 0006-4971